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Introduction {#acr211112-sec-0005}
============

Sarcoidosis is an inflammatory disorder characterized by granulomatous inflammation in affected tissue and can involve nearly any organ. Sarcoidosis can be difficult to treat. Glucocorticoids, which have many adverse effects, are a mainstay of treatment. We and others have shown that Janus kinase--signal transducer and activator of transcription (JAK‐STAT) signaling is constitutively active in sarcoidosis [1](#acr211112-bib-0001){ref-type="ref"}, [2](#acr211112-bib-0002){ref-type="ref"}, [3](#acr211112-bib-0003){ref-type="ref"} as well as granuloma annulare, another granulomatous disease [3](#acr211112-bib-0003){ref-type="ref"}. We hypothesize that JAK‐STAT activation in sarcoidosis is a result of increased production of cytokines, such as interferon‐γ (IFN‐γ) and interleukin 6 (IL‐6), by T cells and macrophages, respectively [3](#acr211112-bib-0003){ref-type="ref"}.

We recently reported remission of refractory cutaneous sarcoidosis during treatment with tofacitinib, a Janus kinase 1 (JAK1) and JAK3 inhibitor, in three consecutive patients [2](#acr211112-bib-0002){ref-type="ref"}, [3](#acr211112-bib-0003){ref-type="ref"}. In these patients, we showed that tofacitinib resulted in histologic resolution of granulomatous inflammation in the skin as well as normalization of JAK‐STAT signaling in the skin and blood [2](#acr211112-bib-0002){ref-type="ref"}, [3](#acr211112-bib-0003){ref-type="ref"}. In six cases of thoracic sarcoidosis, four from lung and two from lymph node biopsies, we showed not only a similar pattern of phosphorylated‐STAT1 (p‐STAT1) and p‐STAT3 activation but also elevated levels of p‐STAT1 and p‐STAT3 as in cutaneous sarcoidosis. We were unable, however, to evaluate in our patients treated with tofacitinib whether internal organ sarcoidosis was also impacted by treatment; thus, it is not known if internal organ sarcoidosis is similarly responsive to tofacitinib. In this report, we evaluate the efficacy of tofacitinib in a single patient with long‐standing multiorgan sarcoidosis recalcitrant to several therapies, including methotrexate, infliximab, and prednisone. The effect of tofacitinib on internal organ sarcoidosis activity was evaluated with serial positron emission tomography--computed tomography (PET‐CT) imaging, and disease activity in the skin and blood was evaluated with serial cellular and molecular analyses before and during treatment.

Methods {#acr211112-sec-0006}
=======

A 60‐year‐old woman with a 21‐year history of severe sarcoidosis involving the lungs, lymph nodes, bone, and skin was treated with tofacitinib. The diagnosis of sarcoidosis was established by multiple biopsies showing noncaseating granulomas. The patient\'s prior and recent treatments are summarized in Figure [1](#acr211112-fig-0001){ref-type="fig"}A. A skin biopsy and plasma were collected, and whole‐body ^18^F‐flurordeoxyglucose PET‐CT was obtained. These studies were repeated after 6 months of tofacitinib therapy to assess the clinical and molecular response.

![Response of sarcoidosis to tofacitinib. **A**, Overview of treatments. Doses for the medications were as follows: tofacitinib (daily dose (milligrams) in the morning/daily dose (milligrams) in the evening), mycophenolate sodium at 720 mg twice daily, prednisone (shown as a daily dose in milligrams), rituximab (1000 mg weekly for 2 weeks, repeated every 5‐6 months), intravenous immunoglobulin (IVIG) (1000 mg divided over 2 days, repeated monthly), methotrexate (12.5 mg/wk), infliximab (5 mg/kg every 4‐8 weeks). PET‐CT, positron emission tomography--computed tomography. **B**, Left panels: clinical photograph of cutaneous involvement by sarcoidosis before treatment (day −1) and after 6 months (day 180) of tofacitinib treatment. Circled areas show where biopsies were performed. In the day 180 photograph, only postinflammatory pigmentation is present clinically, and there was no palpable component to the lesions. Middle panels: hematoxylin and eosin (H&E)--stained skin biopsies showing representative images before treatment (day −1) and after 6 months (day 180) of tofacitinib treatment. Right panels: immunohistochemistry showing phosphorylated‐STAT1 (p‐STAT1) and p‐STAT3 staining before treatment (day −1, upper 2 panels) and after 6 months (day 180, lower 2 panels) of tofacitinib treatment. Activated Janus kinase--signal transducer and activator of transcription (JAK‐STAT) signaling is indicated by nuclear staining. **C**, Levels of soluble interleukin 2 receptor α (sIL‐2R‐α), tumor necrosis factor α (TNF‐α), and C‐X‐C motif chemokine ligand 10 (CXCL10) in plasma (left panel) and cutaneous tissue interstitial fluid (right panel, labeled "lesional") before treatment (day −1) and after 6 months (day 180) of tofacitinib treatment. **D**, Whole‐body ^18^F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) before treatment (day −1) and after 6 months (day 180) of tofacitinib treatment. **E**, Axial view of the lungs showing computed tomography (CT) (left panels) and composite PET‐CT (right panels) before treatment (day −1) and after 6 months (day 180) of tofacitinib treatment. Arrows show areas of disease activity present at baseline. **F**, Tofacitinib can inhibit both Janus kinase 1 (JAK1) and JAK2 activation of STAT1 induced by interferon‐γ as well as JAK1 and JAK2 activation of STAT3 induced by interleukin 6 and, in doing so, disrupts cytokine signaling loops important for granuloma formation and maintenance. Other JAK‐STAT‐dependent cytokines may also be important.](ACR2-2-106-g001){#acr211112-fig-0001}

Plasma was collected after performing density gradient centrifugation on blood collected in EDTA‐coated tubes. Skin biopsies were divided in half. One portion was placed in 10% buffered formalin for histology and immunohistochemistry. The other half was placed in phosphate buffered saline on ice and immediately minced with a sterile scalpel and incubated at 37°C for 1 hour to allow diffusion of soluble factors present in the tissue (tissue interstitial fluid \[TIF\] preparation). TIF and plasma were analyzed using both a 65‐Plex cytokine/chemokine and 14‐Plex soluble cytokine receptor quantification assay (Eve Technologies) (see [1](#acr211112-sup-0001){ref-type="supplementary-material"}). Immunohistochemistry was performed with p‐STAT1 (Tyr701) and p‐STAT3 (Tyr705) antibodies (Cell Signaling Technologies).

Immunohistochemistry was performed using standard methods. The p‐STAT1 antibody recognizes STAT1 only when it is phosphorylated at Tyr701 (Cell Signaling Technologies). The p‐STAT3 antibody recognize STAT3 only when it is phosphorylated at Tyr705 (Cell Signaling Technologies).

For PET‐CT imaging, the patient followed a high‐fat/low‐carbohydrate diet and a prolonged fast of greater than 12 hours, as is the current clinical protocol for sarcoidosis studies [4](#acr211112-bib-0004){ref-type="ref"}. The patient was injected with a standard dose of fluorine‐18‐fluorodeoxyglucose, and imaging from the vertex of the skull to the toes was performed with low‐dose computed tomography and positron emission tomography (PET).

Results {#acr211112-sec-0007}
=======

At the time of our initial evaluation, the patient\'s sarcoidosis was not controlled with a combination of prednisone, mycophenolate sodium, rituximab, and intravenous immunoglobulin (IVIG), which she had been taking for 7 years (Figure [1](#acr211112-fig-0001){ref-type="fig"}A). Because her disease had previously progressed on medications, including methotrexate and infliximab, her prior and current physicians had used alternative agents, such as rituximab and IVIG, commonly used for nerve involvement.

A cutaneous examination revealed numerous subcutaneous nodules and plaques. A skin biopsy showed granulomatous inflammation consistent with sarcoidosis (Figure [1](#acr211112-fig-0001){ref-type="fig"}B), and immunohistochemistry showed the presence of p‐STAT1 and p‐STAT3 staining (Figure [1](#acr211112-fig-0001){ref-type="fig"}B) consistent with activation of JAK‐STAT signaling, as seen in our prior work [2](#acr211112-bib-0002){ref-type="ref"}, [3](#acr211112-bib-0003){ref-type="ref"}. PET‐CT showed intense focal uptake in the lungs, lymph nodes, vertebrae and iliac crest, and subcutaneous tissues consistent with sarcoidosis. It is notable that the above findings were present during treatment with a significantly immunosuppressive regimen (Figure [1](#acr211112-fig-0001){ref-type="fig"}D).

Mycophenolate was discontinued, and tofacitinib, 5 mg twice daily, was initiated. After 1 month, there was improvement in the skin lesions, but after 2 months (when she would have been due for rituximab), she noted worsening arthralgias, and so the tofacitinib was increased to 10 mg twice daily. After 4 months of treatment, there was clinical resolution of cutaneous disease. After 6 months, a biopsy from previously lesional skin revealed histologic resolution of granulomas and reduction in STAT1 and STAT3 activation (Figure [1](#acr211112-fig-0001){ref-type="fig"}B). A measurement of cytokine and soluble protein levels in lesional skin tissue showed a reduction in sarcoidosis biomarkers, including soluble interleukin 2 receptor, tumor necrosis factor α, and C‐X‐C motif chemokine ligand 10 (Figure [1](#acr211112-fig-0001){ref-type="fig"}C). A measurement of cytokine levels in the plasma mirrored the reduction in levels of these sarcoidosis biomarkers observed in the skin on tofacitinib (Figure [1](#acr211112-fig-0001){ref-type="fig"}C). Changes in the levels of other markers observed during treatment can be found in [1](#acr211112-sup-0001){ref-type="supplementary-material"}.

In addition to the skin and plasma analyses, PET‐CT was repeated after 6 months of tofacitinib treatment and showed complete resolution of prior sarcoidosis involvement of subcutaneous tissues and internal organs, including lungs, lymph nodes, and bone (Figure [1](#acr211112-fig-0001){ref-type="fig"}D and E). Focal PET avidity was noted in the skeletal muscle of the tongue, proximal thighs, and left rotator cuff and was felt to be nonspecific. PET‐CT was again performed 3 months later and showed resolution of these nonspecific areas of PET avidity as well as continued remission of sarcoidosis at prior sites of involvement.

The patient remains on tofacitinib, IVIG has been discontinued, and prednisone is being tapered. The dose of tofacitinib has been decreased to 10 mg in the morning and 5 mg at night with stable improvement (Figure [1](#acr211112-fig-0001){ref-type="fig"}A). The patient has tolerated tofacitinib well, with only a urinary tract infection that resolved with antibiotic treatment.

Discussion {#acr211112-sec-0008}
==========

These data demonstrate remission of recalcitrant cutaneous and internal organ sarcoidosis with tofacitinib. Histologic resolution of granulomatous inflammation and a marked decrease in sarcoidosis biomarkers in both blood and tissue were observed. In sarcoidosis, dysregulated cytokines, such as IFN‐γ and IL‐6, which help drive granuloma formation, signal via the JAK‐STAT pathway. Inhibition of this pathway with a JAK inhibitor disrupts these cytokine signals between T cells and macrophages (Figure [1](#acr211112-fig-0001){ref-type="fig"}F). Improvement in concomitant sarcoidosis has also been reported in two patients with myelodysplastic disorders treated with ruxolitinib, a JAK1 and JAK2 inhibitor, and in a third patient with sarcoidosis‐like systemic granulomatosis also treated with ruxolitinib [5](#acr211112-bib-0005){ref-type="ref"}, [6](#acr211112-bib-0006){ref-type="ref"}, [7](#acr211112-bib-0007){ref-type="ref"}.

There is significant emerging evidence that JAK inhibitors are targeted treatment for sarcoidosis, an often‐morbid disease for which there is a paucity of safe, reliably effective therapies. Prospective studies of JAK inhibitors in sarcoidosis are underway (ClinicalTrials.gov identifiers NCT03910543 and NCT03793439).
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